DMPA News and Research

RSS

Health Heroines: Supporting Women and Striving for Universal Health Coverage

In this interview we speak to Ms. Anita Kouvahey-Eklu, a recent Heroines of Health award winner, about her work in addressing gender inequalities within healthcare.

From Women in Global Health 7 Nov 2022

Long-acting contraceptives do not increase risk of HIV, concludes new study

One of the largest and most robust studies on HIV infection rates has concluded that long-acting contraceptives do not increase the risk of contracting HIV.

14 Jun 2019

Study finds common contraceptive shot may increase HIV risk

A recent study found an association between HIV risk and the use of the common birth control medications DMPA, among women from sub-Saharan Africa.

9 Jan 2018

Popular contraceptive shot may raise risk of HIV infection

Transitioning away from a popular contraceptive shot known as DMPA could help protect women in Sub-Saharan Africa and other high-risk regions from becoming infected with HIV, according to a research review published in the Endocrine Society's journal Endocrine Reviews.

4 Jan 2018

Self-injection of contraceptive feasible, acceptable among women in sub-Saharan Africa, research reveals

Self-injection of the contraceptive Sayana® Press is both feasible and highly acceptable among women participating in the first such research study conducted in sub-Saharan Africa, according to results published online by the journal Contraception.

16 Nov 2016

Hormonal contraception may increase susceptibility of women to genital infection

Women account for approximately half of all individuals living with HIV worldwide, and researchers wanted to identify the risk factors that increase susceptibility of women to genital infection.

20 Apr 2016

New study provides biological explanation for how DMPA increases risk of HIV infection

In recent years, evidence has been building that injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera or DMPA) is associated with an increased risk of HIV infection. Now a study published in the September 1st issue of mBio, an online open-access journal of the American Society for Microbiology, provides a biological explanation for the phenomenon.

2 Sep 2015

Injectable hormonal contraceptive appears to increase HIV risk in women

Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving more than 39 500 women published in The Lancet Infectious Diseases has found. Other forms of hormonal contraception, including oral contraceptive pills, do not appear to increase this risk.

12 Jan 2015

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

5 Mar 2014

New progestogen-only treatment effective in stopping acute abnormal uterine bleeding

New research from the Los Angeles Biomedical Research Institute (LA BioMed) found a progestogen-only treatment halted bleeding in women suffering from extremely heavy periods, according to the study published online by the American Journal of Obstetrics and Gynecology.

15 Feb 2013

No added HIV risk with hormonal contraceptives

An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.

18 Apr 2012

Breast cancer screening false positive results may need more follow up: Study

A Danish study of more than 58,000 women found those who had false positive mammograms, meaning the results suggested breast cancer when there was none, had a 67 percent higher risk of developing breast cancer later in life compared with women who had negative mammograms.

5 Apr 2012

Injectable form of progestin may increase breast cancer risk in young women

The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that recent use of a year or more doubles the risk.

5 Apr 2012

DMPA intake may increase risk of periodontitis, gingivitis in women

Injectable progesterone contraceptives may be associated with poor periodontal health, according to research in the Journal of Periodontology. The study found that women who are currently taking depotmedroxyprogesterone acetate (DMPA) injectable contraceptive, or have taken DMPA in the past, are more likely to have indicators of poor periodontal health, including gingivitis and periodontitis, than women who have never taken the injectable contraceptive.

7 Feb 2012

Significant number of young women fail to recognize recent weight gain

Despite popular belief about women's weight concerns, young women commonly fail to recognize recent gain of as many as 11 pounds - putting them at risk for cardiovascular disease and other obesity-related conditions.

11 Jan 2012

$DMPA injectible contraceptive associated with increased risk of bone fracture$

DMPA injectible contraceptive associated with increased risk of bone fracture

A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, and not in combination with estrogens.

7 May 2010

Women using DMPA experience high BMD loss, researchers say

Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.

22 Dec 2009

Emergent BioSolutions receives NIAID funding support for dmPA7909 anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to further the development of one of Emergent’s advanced anthrax vaccine candidates known as dmPA7909.

30 Sep 2009

Researchers identify women at risk of gaining excessive weight with Depo-Provera

Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera or the birth control shot. These findings dispel the myth that all women who use DMPA will gain weight and will help physicians to counsel patients appropriately.

24 Jul 2009

Birth control shot causes significant weight gain

Women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, gained an average of 11 pounds and increased their body fat by 3.4 percent over three years, according to researchers at the University of Texas Medical Branch (UTMB).

4 Mar 2009